

Q-linea to participate in a multi-site public tender in Italy

Q-linea AB (publ) (OMX: QLINEA) today announces participation in the upcoming 5-year Tender at ASL Napoli 2 Nord for 4 rAST systems.

The tender is a consequence the publication of the Regional “GENERAL RECOMMENDATIONS ON LOCAL IMPLEMENTATION OF ANTIBIOTIC THERAPY PROTOCOLS” indicating the need for faster AST results to optimize treatment of critical patients affected by sepsis. Expectations are for the tender submission to be finalized by the end of 2024, while installation and go-live is expected during spring 2025 following the completion of the tender procedure.

“This Tender is another indication of the ever-growing importance of rAST in Italy as a key pillar in the treatment of critical patients and the proper use of antibiotics in Italy”, said Franco Pellegrini, VP Sales EMEA at Q-linea.

For more information, please contact:

Stuart Gander, President & CEO, Q-linea

Stuart.Gander@qlinea.com

+1 857 409 7463

Christer Samuelsson, CFO /IR, Q-linea AB

Christer.Samuelsson@qlinea.com

+46 (0) 70-600 15 20

About Q-linea

Q-linea’s rapid AST system, ASTar[®], accelerates and simplifies the time-sensitive workflows faced during the treatment of patients with bloodstream infections and sepsis. Hospitals use ASTar to vastly reduce the time to optimal antimicrobial therapies and ensure that patients receive the correct treatments sooner — when time matters most. We are helping to create sustainable healthcare, now and in the future, and safeguard the effectiveness of antibiotics for generations to come.

Q-linea is headquartered in Uppsala, Sweden and has regional offices in Italy and the USA, with partnerships worldwide.

ASTar Instrument and ASTar BC G- Consumable kit are CE-IVD marked and FDA 510(k) cleared. For more information, please visit www.qlinea.com

Attachments

[Q-linea to participate in a multi-site public tender in Italy](#)